|
|
Drugs of Tomorrow 2001: Depression - A Future Away From Serotonin?Published by: Datamonitor Published: Mar. 1, 2001 - 205 Pages Table of ContentsTABLE OF CONTENTS EXECUTIVE SUMMARY Report summary Introduction Patient potential in depression and its comorbid disorders Unmet needs in depression Investors in depression Drug class focus Future market leaders R&D opportunities in depression DEPRESSION OVERVIEW Definition of depression and its comorbid conditions Major depression Social anxiety disorder Generalized anxiety disorder Panic disorder Obsessive compulsive disorder Post-traumatic stress disorder Attention deficit hyperactivity disorder Premenstrual dysphoric disorder Bulimia nervosa Agoraphobia Epidemiology of depression The prevalence of major depression Comorbidity of mood disorders Classification of pipeline products Serotonergics Noradrenergics Reversible monoamine oxidase inhibitors NK-1 Substance P antagonists Other antidepressants Clinical endpoints in depression and anxiety Hamilton Rating Scale for Depression Hamilton Rating Scale for Anxiety The Zung Self-Rating Depression Scale The Beck Depression Index Internet rating scales Suicide rates Unmet needs in depression Side effects of existing treatments Onset action of current treatment Screening facilities Low diagnosis rates Refractory depression DEPRESSION PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in depression Key R&D protocol strategies in depression Key drug delivery strategies in depression Key licensing strategies in depression Pipeline analysis by class Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company DRUG ANALYSIS New antidepressant drugs Serotonergics Escitalopram Key preclinical development projects Recently discontinued projects Noradrenergics Duloxetine (LY248686) MCI 225 NK-1 Substance P antagonists Merck's Substance P NKP 608 TAK-637 Recently discontinued projects Monoamine oxidase-A inhibitors Befloxatone Eldepryl (selegiline hydrochloride) NS 2389 Key preclinical/research development projects Recently discontinued projects 5-HT agonist Sunepitron (CP-93-393) Gepirone (BMY-13805) DU 125530 Alnespirone (S 20499) Robalzotan (NAD 299) Key phase I development projects Key preclinical/research development projects Recently discontinued projects Others Igmesine (JO 1784/CI 1019) YM 992 Pregabalin EMD 688 NBI 30775 Key phase I development projects Key preclinical/research development projects Recently discontinued projects COMPARATIVE ANALYSIS Comparison by class Treatment refractory depression Side effect profile Onset of action Mechanism of action Marketing strength Comparative analysis of noradrenergics Comparison of side effects in the noradrenergic class Comparison of the onset of action in the noradrenergic class Comparison of mechanism of action in the noradrenergic class Comparison of marketing strength in the noradrenrgic class Comparative analysis of NK-1 Substance P antagonists Comparison of side effects in the NK-1 Substance P antagonist class Comparison of the onset of action in the NK-1 Substance P antagonist class Comparison of mechanism of action in the NK-1 Substance P antagonist class Comparison of marketing strength in the NK-1 Substance P antagonist class Comparative analysis of reversible MAOIs Comparison of side effects in the reversible MAOIs class Comparison of the onset of action in the reversible MAOIs class Comparison of mechanism of action in the reversible MAOIs class Comparison of marketing strength in the reversible MAOIs class Comparative analysis of 5-HT agonists and single isomer serotonergics Comparison of drug delivery methods, side effects, onset of action and mechanism of action in the 5-HT agonist and single isomer serotonergic class Comparison of marketing strength in the 5-HT agonist class Comparative analysis of other antidepressants Comparison of side effects in the other antidepressants class Comparison of the onset of action in the other antidepressants class Comparison of mechanism of action in the other antidepressants class Comparison of marketing strength in the other antidepressants class FUTURE FOCUS IN DEPRESSION Market drivers in depression Patent expiries Multiple indications of antidepressants Reformulations of marketed antidepressants Currently marketed products launching onto new markets Reimbursement and pricing issues Future trends in the prevalence of depression and its comorbid disorders Prospective drug launches in depression Launch forecast methodology Forecast launches in depression from 2001 to 2007 Market forecasts (2001-2007) Forecast methodology Depression market forecasts (2001-2007) Antidepressant class and drug forecasts, 2001-2007 Long term potential of phase I and preclinical compounds APPENDIX Clinical trial data bibliography Epidemiological bibliography Forecasting drug launches for antidepressant drugs in development Global highest stage of development Reclassification of development phases Primary delivery classifications List of tables (c) Datamonitor 2000. All Rights Reserved. AbstractDrugs of Tomorrow 2001: Depression - A Future Away From Serotonin? is a comprehensive analysis of the current depression pipeline. The report focuses on new products at phase II or above and provides an in-depth review of the current status and future potential of each drug. This allows an overall view of the antidepressant market to be formulated.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||